Welcome to our dedicated page for Sarepta Therapeutics SEC filings (Ticker: SRPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Sarepta Therapeutics’ SEC disclosures often means sifting through pages on exon skipping science, gene therapy batch yields, and multi-year cash burn tables. If you’ve ever typed “Sarepta Therapeutics SEC filings explained simply” into a search bar, you already know the challenge. Stock Titan’s AI tackles that complexity head-on, turning dense research updates into plain-English highlights that focus on Duchenne muscular dystrophy trials, FDA milestones, and collaboration revenue streams.
Need the numbers fast? Our platform pulls every “Sarepta Therapeutics quarterly earnings report 10-Q filing” as soon as it hits EDGAR and pairs it with instant ratio analysis. Real-time alerts for “Sarepta Therapeutics Form 4 insider transactions real-time” let you see when directors buy ahead of pivotal readouts. Use AI-powered summaries to move from headline to detail across all major forms:
- Sarepta Therapeutics annual report 10-K simplified—cash runway, pipeline probability tables, and manufacturing capacity.
- Sarepta Therapeutics proxy statement executive compensation—compare leadership incentives to clinical milestones.
- Sarepta Therapeutics 8-K material events explained—FDA decisions, partnership payments, or safety updates within minutes.
The result: one page that answers the questions investors actually ask—“How did Exondys 51 sales shift this quarter?” or “What do Sarepta Therapeutics insider trading Form 4 transactions signal ahead of an FDA advisory meeting?” Whether you’re tracking “Sarepta Therapeutics executive stock transactions Form 4” or need a deep “Sarepta Therapeutics earnings report filing analysis,” our AI shows you the story behind the numbers. Start “understanding Sarepta Therapeutics SEC documents with AI” today and make faster calls on gene-therapy breakthroughs without reading hundreds of pages first.
The Vanguard Group filed Amendment No. 11 to Schedule 13G for Sarepta Therapeutics, Inc. (SRPT), reporting ownership of 10,641,733 shares, equal to 10.89% of the outstanding common stock. Vanguard reports 0 sole voting power, 606,072 shared voting power, 9,925,846 sole dispositive power, and 715,887 shared dispositive power. The filing states these shares are held in the ordinary course of business and are not intended to influence control of the issuer. The filing identifies Vanguard's Malvern, PA address and is signed by Ashley Grim, Head of Global Fund Administration, dated 09/08/2025.
Louise Rodino-Klapac, President of R&D and Tech Ops at Sarepta Therapeutics (SRPT), reported insider acquisitions on Form 4. On 09/03/2025 she was granted two awards of restricted stock units (RSUs): 93,875 RSUs that vest 50% on 09/03/2026 and 50% on 09/03/2027, and 50,000 performance-based RSUs that vest 100% on 09/03/2028 subject to service and achievement of performance criteria. The transactions were reported as acquisitions at $0 per share because they are equity awards. Following the grants and an earlier purchase of 106 shares on 08/31/2025 under the ESPP, she beneficially owned 228,612 shares after the reported transactions.
Ryan Ho-Yan Wong, Chief Financial Officer of Sarepta Therapeutics (SRPT), reported grants of restricted stock units on 09/03/2025. He received 93,875 RSUs that vest 50% on 09/03/2026 and 50% on 09/03/2027, and an additional 25,000 performance-based RSUs that vest 100% on 09/03/2028 only if certain performance criteria are met and he remains in service. The reported price for both grants is $0. Following the 09/03/2025 transactions, the filing shows beneficial ownership totaling 136,203 shares. The Form 4 was signed by an attorney-in-fact on 09/05/2025.
Ian Michael Estepan, Chief Operating Officer of Sarepta Therapeutics (SRPT), reported two grants of restricted stock units on 09/03/2025. He received 93,875 RSUs that vest 50% on 09/03/2026 and 50% on 09/03/2027. He also received 50,000 performance-based RSUs that vest 100% on 09/03/2028 subject to service and performance committee approval. Following the grants his beneficial ownership increased to 156,487 shares and then to 206,487 shares. The Form 4 was signed by an attorney-in-fact on 09/05/2025. All RSUs are at $0 reported price because they are awards, not purchases.
Cristin Rothfuss, EVP and General Counsel of Sarepta Therapeutics (SRPT), received stock awards totaling 118,875 restricted stock units (RSUs) on a transaction dated 09/03/2025. The awards consist of 93,875 RSUs that vest 50% on 09/03/2026 and 50% on 09/03/2027 subject to continued service, and 25,000 performance-based RSUs that vest 100% on 09/03/2028 only if performance criteria are met and the Reporting Person remains in service. Each RSU represents the right to one share and the grants were reported with a $0 purchase price. Following these grants, the Reporting Person beneficially owned 139,985 shares.
Sarepta Therapeutics filed a Current Report on Form 8-K disclosing an indenture dated August 28, 2025 with U.S. Bank Trust Company, National Association as trustee that includes the form of a 4.875% Convertible Senior Note due 2030. The filing references the form of the note as included in Exhibit 4.1. The report is signed by Ian Estepan, President and Chief Operating Officer.
Sarepta Therapeutics filed an 8-K that references its quarterly report on Form 10-Q for the period ended
The notice functions as a routine corporate disclosure: it directs readers to the company’s subsequent SEC filings for updates and establishes the date of the forward-looking statement safe-harbor. No financial results, transactions, or new material agreements are disclosed in the provided text.
Sarepta Therapeutics announced the planned departure of Bilal Arif, its Executive Vice President and Chief Technical Operations Officer, as part of a strategic restructuring and pipeline prioritization. Mr. Arif served in the role through August 12, 2025, will remain a Special Advisor until his employment ends on September 16, 2025, and will provide consulting services through December 31, 2025. The company and Mr. Arif executed a Separation and Consulting Agreement dated August 12, 2025, under which he will receive a lump-sum severance payment of $576,700 and a consulting fee of $400 per hour. Outstanding equity awards will continue to vest while he remains employed or provides consulting services. The full agreement will be filed as an exhibit to the Company’s Quarterly Report for the quarter ended September 30, 2025.
Sarepta Therapeutics received a Schedule 13G/A from Capital International Investors disclosing a passive, beneficial holding of 524,146 common shares, equal to 0.5% of the 98,277,032 shares reported outstanding. The filing identifies Capital International Investors as a division of Capital Research and Management Company and related investment management entities and states that those entities are collectively deemed the beneficial owner of the position.
The report shows detailed control metrics: sole voting power for 523,807 shares, sole dispositive power for 524,146 shares and no shared voting or dispositive power. The filing also certifies the shares are held in the ordinary course of business and not to change or influence control of the issuer.
Sarepta Therapeutics (SRPT) Form 4 filing: Chief Technology Operations Officer Bilal Arif reported the award of 6,250 Performance Stock Units (PSUs) on 08/05/2025. The grant originates from a March 1 2024 PSU agreement; shares earned were approved by the Compensation Committee based on milestone achievement. The PSUs convert 1-for-1 into common stock and will vest on 03/01/2026, contingent on continued employment. Following the transaction, Arif directly holds 6,250 derivative securities; no shares were sold and no cash price was paid, indicating this is an incentive, not a market purchase. No changes to common-stock ownership were disclosed.
The filing signals ongoing executive retention and alignment with long-term performance targets but does not materially affect share count or near-term earnings. Investors typically view such equity awards as neutral unless unusually large relative to existing float.
FAQ
What is the current stock price of Sarepta Therapeutics (SRPT)?
What is the market cap of Sarepta Therapeutics (SRPT)?
